BJ93.F · Benitec Biopharma Inc

-

Please sign in to comment on BJ93.F

1 Comment

Admin

4 years ago

Benitec Biopharma Inc is currently in a long term downtrend where the price is trading 2.2% below its 200 day moving average.

From a valuation standpoint, the stock is 81.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 238.1.

Benitec Biopharma Inc's total revenue sank by 98.7% to $1K since the same quarter in the previous year.

Its net income has dropped by 51.3% to $-3M since the same quarter in the previous year.

Finally, its free cash flow fell by 11.3% to $-4M since the same quarter in the previous year.

Based on the above factors, Benitec Biopharma Inc gets an overall score of 1/5.

Exchange	F
CurrencyCode	EUR
ISIN	US08205P1003
Sector	Healthcare
Industry	Biotechnology

Market Cap	302K
PE Ratio	None
Target Price	None
Dividend Yield	0.0%
Beta	1.05

ABOUT

Benitec Biopharma Inc

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

BJ93.F · Benitec Biopharma Inc

-

Benitec Biopharma Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Benitec Biopharma Inc using a moving average strategy